AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors

被引：0

作者：

Dowlati, A. ^{[1
]}

Richardson, D. L. ^{[2
]}

Lorusso, P. ^{[3
]}

Spira, A. I. ^{[4
]}

Bashir, B. ^{[5
]}

Hirmand, M. ^{[6
]}

Mehta, M. ^{[6
]}

Patel, M. R. ^{[7
]}

机构：

[1] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH USA

[2] Univ Oklahoma, Gynecol Oncol Sect, Dept Obstet & Gynecol Sect Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA

[3] Yale Univ, Dept Med Oncol, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT USA

[4] Virginia Canc Specialists, VCS Res Inst, Fairfax, VA USA

[5] Thomas Jefferson Univ, Div Solid Tumors, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA USA

[6] Avenzo Therapeut Inc, Clin Dev, San Diego, CA USA

[7] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.386

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

439TiP

引用

页码：S405 / S405

页数：1